17:17 , May 26, 2017 |  BC Week In Review  |  Clinical News

Inovio reports Phase I data for HIV vaccine Pennvax-GP

Inovio Pharmaceuticals Inc. (NASDAQ:INO) said data from the Phase I HVTN 098 trial in 94 healthy, HIV-uninfected volunteers showed that HIV vaccine Pennvax-GP produced "amongst the highest overall levels" of cellular and antibody immune response...
22:48 , May 24, 2017 |  BC Extra  |  Clinical News

Inovio gains on HIV vaccine data

Inovio Pharmaceuticals Inc. (NASDAQ:INO) gained $1.55 (22%) to $8.68 on Wednesday after it said data from a Phase I study in healthy volunteers showed that HIV vaccine Pennvax-GP produced "amongst the highest overall levels" of...
07:00 , Jul 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: HIV env; HIV gag polyprotein; HIV pol; HIV gp140

Infectious disease INDICATION: HIV / AIDS Non-human primate studies identified a prime-boost vaccine protocol that could help prevent HIV infection. In a monkey model of SIV infection, two priming immunizations with an adenoviral vaccine encoding SIV env,...
08:00 , Nov 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS HIV gag polyprotein; HIV p27 (nef); HIV pol; HIV env Macaque studies suggest mosaic HIV...
07:00 , Mar 18, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HIV/AIDS HIV gag; HIV p27 (nef); HIV pol; HIV env Two studies in macaques suggest that...
07:00 , Mar 18, 2010 |  BC Innovations  |  Cover Story

Creating a mosaic in HIV

U.S. researchers have shown that engineered, mosaic HIV vaccines could offer a better in vivo immune response to the virus than vaccines based on natural HIV epitopes.1,2 The nearly universal mosaic vaccines trigger a broad...